Xenon Pharmaceuticals (NASDAQ:XENE) Issues Earnings Results, Beats Expectations By $0.02 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.02, FiscalAI reports.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Azetukalner’s focal-seizure NDA has been submitted, supported by two pivotal trials that Xenon says showed statistically significant seizure reductions across all tested doses and a consistent safety profile across more than 1,500 patient-years. The company is preparing for a potential U.S. launch.
• Xenon plans to start the X-FIRST study in Q1 2027 to assess azetukalner as a first add-on therapy earlier in the focal-seizure treatment journey, while its X-TOLE3 and X-ACKT Phase III studies continue. The company views these trials as opportunities to broaden the drug’s reach.
• Psychiatry remains uncertain: after neuropsychiatric adverse events led to a voluntary pause in new enrollment in MDD and bipolar-depression studies, Xenon expects X-NOVA2 results in December 2026 and plans to review them with the DSMB and FDA before deciding next steps.
• Phase I results for pain candidates XEN1701 (NaV1.7) and XEN1120 (Kv7) supported moving both into acute-pain Phase II proof-of-concept studies, which Xenon expects to initiate in the first half of 2027. The company reported generally favorable tolerability, though efficacy in people with pain has not yet been established.
• Xenon reported $1.2 billion in cash, cash equivalents and marketable securities, which it expects to fund operations into 2029, including the azetukalner launch preparations and advancement of its pipeline.

Xenon Pharmaceuticals Stock Performance

Shares of Xenon Pharmaceuticals stock opened at $40.45 on Tuesday. The stock has a market capitalization of $3.91 billion, a P/E ratio of -8.53 and a beta of 0.11. Xenon Pharmaceuticals has a 52-week low of $33.38 and a 52-week high of $72.66. The stock’s 50-day simple moving average is $42.64 and its 200 day simple moving average is $52.14.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CFO Thomas Patrick Kelly bought 15,000 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was purchased at an average price of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the transaction, the chief financial officer directly owned 15,000 shares of the company’s stock, valued at $559,800. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Ian Mortimer bought 30,000 shares of Xenon Pharmaceuticals stock in a transaction dated Wednesday, September 30th. The stock was acquired at an average price of $37.38 per share, with a total value of $1,121,400.00. Following the purchase, the chief executive officer directly owned 49,923 shares of the company’s stock, valued at approximately $1,866,121.74. This represents a 150.58% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 2.91% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on XENE. HC Wainwright reissued a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Wall Street Zen cut shares of Xenon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Sunday, October 11th. Needham & Company LLC lowered their price target on shares of Xenon Pharmaceuticals from $78.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, September 18th. Guggenheim began coverage on Xenon Pharmaceuticals in a research note on Tuesday, October 6th. They issued a “buy” rating and a $73.00 price objective on the stock. Finally, Royal Bank Of Canada dropped their price objective on Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating on the stock in a research note on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.31.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells.

Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions.

Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.